REBUILDCNS
Financiado
Redirecting glial progenitor fate to rebuild the injured Brain
Over a million different cell types and billions of connections underlie brain function. While the embryonic brain glial progenitors generate this cellular diversity, in the adult brain progenitor competence becomes restricted to...
Over a million different cell types and billions of connections underlie brain function. While the embryonic brain glial progenitors generate this cellular diversity, in the adult brain progenitor competence becomes restricted to generation of few cell types. Thus, any attempt to repair the brain requires knowledge of the rules governing fate decisions within a damaged environment. We have shown that injury activates an inflammatory transcriptional signature in glial progenitors leading to exit from a dormant state. Excitingly, our recent data indicates that injury leads to demethylation of developmental enhancers in these glial progenitors too. In the regenerating zebrafish, activation of enhancers drives a transcriptional regenerative program. Yet, in rodents, despite enhancer demethylation by injury, transcription of a developmental program is missing. The overall goal of this project is to envisage ways to efficiently commission enhancers to re-direct lineage choices of glial progenitors towards re-establishing brain function following injury. Recent technological breakthroughs, including clonal lineage tracing, genome editing, and single cell omics combined with mouse genetics and injury models will allow (i) analysis of fate choices in the naïve and injured CNS (ii) study of how the chromatin landscape impacts transcriptional modulation of cell identity (iii) to finally design an integrated manipulation of the epigenome, transcriptome and environment for directed brain repair by endogenous progenitors.
We follow a multidisciplinary approach combining cutting edge technology in functional genomics, developmental biology and translational research and leverage on a set of cutting-edge experimental platforms established in my lab and validated protocols that have led to exciting preliminary discoveries.
We will provide fundamental knowledge on the mechanisms underlying lineage-decisions of CNS progenitors and open new research lines for treating CNS disorder
ver más
Duración del proyecto: 64 meses
Fecha Inicio: 2018-01-15
Fecha Fin: 2023-05-31
Fecha Fin: 2023-05-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2023-05-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2017-COG:
ERC Consolidator Grant
Cerrada
hace 7 años
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
9.76M€ |
Participante